Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare’s ESA Proposal Relies Too Much On Off-Label Data, Amgen Says

Executive Summary

CMS improperly applies safety data from off-label uses of erythropoiesis-stimulating agents to chemotherapy-induced anemia in its recent proposed national coverage determination on ESAs, Amgen maintains

You may also be interested in...



Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen

Commercial insurers are unlikely to follow CMS' recent national coverage determination on erythropoiesis-stimulating agents for non-renal disease uses, Amgen is predicting

Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen

Commercial insurers are unlikely to follow CMS' recent national coverage determination on erythropoiesis-stimulating agents for non-renal disease uses, Amgen is predicting

Senate Finance Committee Is Not SquWeemish About CMS Nominee

CMS Administrator-Nominee Kerry Weems faced no serious challenges during a July 25 confirmation hearing held by the Senate Finance Committee, with most of his comments focusing on a pledge to emphasize oversight of CMS programs

Related Content

UsernamePublicRestriction

Register

PS048470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel